Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01838668 : An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
PhasePhase 3
AgesMin: 18 Years Max: 55 Years
Eligibility
Key Inclusion Criteria:

- Inclusion Criteria for Part I:

- Must have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS).

- Must have a baseline Expanded Disability Status Scale (EDSS) score between 0.0
and 5.0, inclusive.

Key Inclusion Criteria for Part II:

• Subjects who participated in and completed Part I per protocol.

Key Exclusion Criteria:

- Other chronic disease of the immune system, malignancies, acute urologic, pulmonary,
gastrointestinal disease.

- Pregnant or nursing women.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01838668      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740